Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis
نویسندگان
چکیده
Objective Diffuse cutaneous systemic sclerosis (SSc) is a highly heterogeneous disease. A provisionally approved Composite Response Index in diffuse SSc (CRISS) was developed as 1-year outcome measure for clinical trials. Our goal to further validate the CRISS by examining agreement between definitions improved/non-improved with physicians' evaluation of Methods Patient profiles from large observational cohort were created 50 random patients <5 years disease duration improved scores after 1 year and non-improved scores. Profiles described features used during initial development at baseline year. Each profile independently rated 3 expert physicians. Majority opinion determined whether patient or not improved, kappa cutoff 0.6 calculated. Results Patients had mean ± SD 2.2 1.3 years. There substantial physician majority about each case (κ = 0.76 [95% confidence interval (95% CI) 0.64–0.88]). The individual also 0.70 CI 0.62–0.78]). All non-improvers majority; however, 12 improvers Conclusion dichotomous rating assessment This supports use improvement versus non-improvement, although tended rate more than did
منابع مشابه
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
OBJECTIVE Early diffuse cutaneous systemic sclerosis (dcSSc) is characterized by rapid changes in the skin and internal organs. The objective of this study was to develop a composite response index in dcSSc (CRISS) for use in randomized controlled trials (RCTs). METHODS We developed 150 paper patient profiles with standardized clinical outcome elements (core set items) using patients with dcS...
متن کاملDisease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis
BACKGROUND Systemic sclerosis (SSc)-overlap syndromes are a very heterogeneous and remarkable subgroup of SSc-patients, who present at least two connective tissue diseases (CTD) at the same time, usually with a specific autoantibody status. OBJECTIVES To determine whether patients, classified as overlap syndromes, show a disease course different from patients with limited SSc (lcSSc) or diffu...
متن کاملEXTENDED REPORT Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis
Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis Pia Moinzadeh, Elisabeth Aberer, Keihan Ahmadi-Simab, Norbert Blank, Joerg H W Distler, Gerhard Fierlbeck, Ekkehard Genth, Claudia Guenther, Ruediger Hein, Joerg Henes, Lena Herich, Ilka Herrgott, Ina Koetter, Alexander Kreuter, Thomas Krieg, Kathrin Kuhr, ...
متن کاملAssociation between atherosclerosis and parenchymal lung involvement in systemic sclerosis
Background: Systemic sclerosis is an autoimmune disease affecting connective tissues, (including epidermal, subepidermal, microvasculature, etc.), leading to various extent of end-organ damage. The leading cause of mortality among these patients is lung involvement. The cardiovascular events happen more frequently in patients suffering systemic scleroderma, comparing to healthy population. This...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arthritis Care and Research
سال: 2022
ISSN: ['1529-0123', '0893-7524', '2151-4658', '2151-464X']
DOI: https://doi.org/10.1002/acr.24638